Tobacco use and cessation for cancer survivors: An overview for clinicians
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Answer questions and earn CME/CNE Approximately 30% of all cancer deaths in the United States are caused by tobacco use and smoking. Cancers of eighteen sites have been causally linked to smoking, the most common of which are the lung, head and neck, bladder, and esophagus. While quit rates and quit attempt rates are relatively high shortly after a cancer diagnosis, the recidivism rates are also high. Therefore, screening, treating, and preventing relapse to tobacco use is imperative among patients with and survivors of cancer. To date, research has consistently shown that a combination of pharmacologic and behavioral interventions is needed to achieve the highest smoking cessation rates, with a recent emphasis on individualized treatment as a most promising approach. Challenges in health care systems, including the lack of appropriate resources and provider training, have slowed the progress in addition to important clinical considerations relevant to the treatment of tobacco dependence (eg, a high degree of comorbidity with psychiatric disorders and other substance use disorders). However, continued tobacco use has been shown to limit the effectiveness of major cancer treatments and to increase the risk of complications and of developing secondary cancers. The authors recommend that oncology providers screen all patients for tobacco use and refer users to specialized treatment when available. Alternatively, oncology clinicians can provide basic advice on tobacco use cessation and pharmacotherapy and/or referral to outside resources (eg, quitlines). Herein, the authors summarize the current knowledge on tobacco use and its treatment, with a focus on the related available evidence for patients with and survivors of cancer. CA Cancer J Clin 2014;64:272–290. © 2014 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
Actual Causes of Death in the United States, 2000
Mokdad, A. H. (2004) · JAMA · doi:10.1001/jama.291.10.1238 · Cited by 5,211
The “Meaningful Use” Regulation for Electronic Health Records
Blumenthal, D., & Tavenner, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006114 · Cited by 2,059
BARKLEY, R. A., FISCHER, M., EDELBROCK, C. S., & SMALLISH, L. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00007 · Cited by 1,507
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243 · cited 1×
“78 [N 5 1272).(131) Although 2 small trials are reported in patients with and survivors of cancer treated with varenicline successfully,(132,133) the finding that a low dosage of varenicline causes fewer severe side effects is particularly important to keep in mind when prescribing it in the oncology setting due to th…”
BackgroundSmoking, smoking cessation, and major depression
Glassman, A. H. (1990) · JAMA · doi:10.1001/jama.1990.03450120058029 · Cited by 1,207
Understanding the potential of teachable moments: the case of smoking cessation
McBride, C. M. (2003) · Health Education Research · doi:10.1093/her/18.2.156 · Cited by 1,162
Nicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Smoking and Major Depression: A Causal Analysis
Kendler, K. S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130038007 · Cited by 792
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Parsons, A., Daley, A., Begh, R., & Aveyard, P. (2010) · BMJ · doi:10.1136/bmj.b5569 · Cited by 696
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer
Browman, G. P., Wong, G., Hodson, I., Sathya, J., Russell, R., McAlpine, L., Skingley, P., & Levine, M. N. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280302 · Cited by 600 · cited 1×
“In addition, in other studies, patients with cancer who were active smokers during cancer treatment had lower response rates to radiation therapy compared with former smokers and recent quitters who stopped smoking before starting treatment.(57,58) Common side effects of radiation such as oral mucositis, xerostomia, w…”
ResultAntidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567 · cited 1×
“unable to achieve cessation with first-line agents who are willing to consider another pharmacotherapy.(121,179,180) Nortriptyline and clonidine are available in generic form,”
BackgroundTopiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Volkow, N. D., Wang, G., Fowler, J. S., Tomasi, D., Telang, F., & Baler, R. (2010) · BioEssays · doi:10.1002/bies.201000042 · Cited by 532
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Schroeder, S. A., & Morris, C. D. (2010) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.012809.103701 · Cited by 349 · cited 1×
“Even more dramatic is that one of 3 individuals with a mental health disorder is a current smoker (33%) in contrast to one of 5 (20%) in the general population.(90,91) In a nationally representative sample, current smokers diagnosed with a mental disorder within the past month accounted for 44% of all cigarettes consu…”
ResultKotz, D., Brown, J., & West, R. (2014) · Addiction · doi:10.1111/add.12429 · Cited by 283
Smoking at diagnosis and survival in cancer patients
Warren, G. W., Kasza, K. A., Reid, M. E., Cummings, K. M., & Marshall, J. R. (2013) · International Journal of Cancer · doi:10.1002/ijc.27617 · Cited by 265 · cited 2×
“36).(4) In recent years, screening for tobacco use in cancer settings has been emphasized,(24) and although progress has been made, more system-wide changes need to occur to reach universal screening.”
BackgroundEfficacy of a nicotine lozenge for smoking cessation
Shiffman, S., Dresler, C. M., Hajek, P., Gilburt, S. J. A., Targett, D. A., & Strahs, K. R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.11.1267 · Cited by 265
Internet-based interventions for smoking cessation
Civljak, M., Stead, L. F., Hartmann-Boyce, J., Sheikh, A., & Car, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007078.pub4 · Cited by 249
Cryan, J. F., Bruijnzeel, A. W., Skjei, K. L., & Markou, A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1445-7 · Cited by 223
Hyperactive Boys and Their Brothers: A 25-Year Follow-Up Study
Borland, B. L. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060013002 · Cited by 208
Gunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009) · BMJ · doi:10.1136/bmj.b3805 · Cited by 200
Smoking and the Risk of Suicidal Behavior: A Prospective Study of a Community Sample
Breslau, N., Schultz, L. R., Johnson, E. O., Peterson, E. L., & Davis, G. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.3.328 · Cited by 175
Williams, J. M., Anthenelli, R. M., Morris, C. D., Treadow, J., Thompson, J. R., Yunis, C., & George, T. P. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07522 · Cited by 162 · cited 1×
“The third study, done in stable patients with schizophrenia in a multisite controlled trial, resulted in lower abstinence with varenicline than in the general population, at 19% versus 5% for placebo, but with no difference noted in the exacerbation of psychotic symptoms.(154) Finally, another large multisite study, c…”
ResultSmoking relapse during the first year after treatment for early-stage non-small-cell lung cancer
Walker, M. S., Vidrine, D. J., Gritz, E. R., Larsen, R. J., Yan, Y., Govindan, R., & Fisher, E. B. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0509 · Cited by 147
Self-citationTonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010) · Drug Safety · doi:10.2165/11319180-000000000-00000 · Cited by 142
Varenicline, Smoking Cessation, and Neuropsychiatric Adverse Events
Gibbons, R. D., & Mann, J. J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12121599 · Cited by 142 · cited 1×
“Two reanalyses of existing databases did not show an increase in neuropsychiatric events with varenicline compared with placebo, mostly in patients without a psychiatric history or psychiatric symptoms, and varenicline seemed to reduce the impact of nicotine withdrawal and the occurrence of neuropsychiatric events (eg…”
Cinciripini, P. M., Robinson, J. D., Karam-Hage, M., Minnix, J. A., Lam, C., Versace, F., Brown, V. L., Engelmann, J. M., & Wetter, D. W. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.678 · Cited by 136
Self-citationComparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics
Smith, S. S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.426 · Cited by 132
What makes for an effective stop-smoking service?
Brose, L. S., West, R., McDermott, M. S., Fidler, J. A., Croghan, E., & McEwen, A. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200251 · Cited by 110
Kessler, R. C., Borges, G., Sampson, N., Miller, M., & Nock, M. K. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.78 · Cited by 81
Pell, J., Haw, S., Cobbe, S., Newby, D., Pell, A., Oldroyd, K., Murdoch, D., Pringle, S., Dunn, F., MacIntyre, P., et al. (2008) · Nicotine & Tobacco Research · doi:10.1080/14622200802023858 · Cited by 57
The Relation between Nicotine Dependence and Suicide Attempts in the General Population
Yaworski, D., Robinson, J., Sareen, J., & Bolton, J. M. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600306 · Cited by 53 · cited 1×
“Furthermore, nicotine dependence has the third-highest population-attributable fraction for suicide attempts of any psychiatric disorder, after major depressive disorder and borderline personality disorder, even higher than that of posttraumatic stress disorder.(145) Recently, a very large Veterans Health Administrati…”
Background
Cited by
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Quinn, G. P., Sanchez, J. A., Sutton, S. K., Vadaparampil, S. T., Nguyen, G. T., Green, B. L., Kanetsky, P. A., & Schabath, M. B. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21288 · Cited by 479
Hutchcraft, M. L., Teferra, A. A., Montemorano, L., & Patterson, J. G. (2021) · LGBT Health · doi:10.1089/lgbt.2020.0185 · Cited by 47
“tobacco use,(21,26,27) which may partially explain differences in chronic conditions, increase complications from cancer treatment, and influence survival.(47) Lesbian women reported worse self-rated health than heterosexual women.”
Background
Metadata
- Authors
- Karam‐Hage, M., Cinciripini, P. M., & Gritz, E. R.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2014-05-09
- Volume
- 64
- Issue
- 4
- Pages
- 272-290
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W1939896399
- Cited by
- 121
- References
- 39
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.